| Chemical & Physical Properties | |
|---|---|
| CAS Number | 636582-62-2 |
| Catalog No. | 2A-0200753 |
| Chinese Name | 莫沙必利 柠檬酸盐 |
| Synonyms | Target; 5-HT4 Receptor; References |
| Molecular Formula | C26H33ClFN3O6 |
| Molecular Weight | 650.05 |
| Purity | ≥98 (HPLC) |
| Melting Point | 112-114°C |
| Appearance | solid |
| Storage Condition | 2-8°C |
| Application | Mosapride citrate (TAK-370) dehydrate is a prokinetic drug with 5-hydroxytryptamine 4 receptor agonist activity and has been widely used in the research of various gastrointestinal diseases. Mosapride |
| PubChem ID | 329817957 |
| MDL Number | MFCD00874415 |
| SMILES | O.O.OC(=O)CC(O)(CC(O)=O)C(O)=O.CCOc1cc(N)c(Cl)cc1C(=O)NCC2CN(CCO2)Cc3ccc(F)cc3 |
| InChI | 1S/C21H25ClFN3O3.C6H8O7.2H2O/c1-2-28-20-10-19(24)18(22)9-17(20)21(27)25-11-16-13-26(7-8-29-16)12-14-3-5-15(23)6-4-14;7-3(8)1-6(13,5(11)12)2-4(9)10;;/h3-6,9-10,16H,2,7-8,11-13,24H2,1H3,(H,25,27);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);2*1H2 |
| InChI Key | KVKIQHMTGSGTFO-UHFFFAOYSA-N |
| NACRES Code | NA.77 |
| UNSPSC | 12352200 |
| Hazard Symbols | transportation |
| MSDS | msds/202582_1_636582_62_2.pdf |
| Bioactivity | Mosapride (TAK-370) citrate dehydrate is a gastroprokinetic agent with 5-hydroxytryptamine4 receptor agonist activity and has been widely used in the research of a variety of gastrointestinal disorders. Mosapride citrate dihydrate potently inhibits Kv4.3 in a concentration-dependent manner with IC50 values of 15.2 μM[1]. Mosapride citrate dihydrateselectively stimulates upper GI motility in vivo[2]. Related Catalog Research Areas >> Metabolic Disease Signaling Pathways >> Membrane Transporter/Ion Channel >> Potassium Channel Signaling Pathways >> GPCR/G Protein >> 5-HT Receptor Signaling Pathways >> Neuronal Signaling >> 5-HT Receptor Target 5-HT4 Receptor Kv4.3:15.2 μM (IC50) In Vitro Mosapride (0.3-30 μM) exhibits an inhibitory activity against Kv4.3 with an IC50 of 15.2 μM in a concentration-dependent manner. Mosapride also inhibits the open state of Kv4.3 currents during depolarization and accelerates the closed-state inactivation at subthreshold potentials[1]. In Vivo Mosapride (Intravenous injection;0.3-3 mg/kg) dose-dependently increases the antral motor activity in conscious dogs which indicates that mosapride selectively stimulates upper gastrointestinal motility[2]. Animal Model: Beagle dogs[2] Dosage: 0.3-3 mg/kg Administration: Intravenous injection; 0.3-3 mg/kg Result: Increased the antral motor activity dose-dependently in conscious dogs. References [1]. Sung KW, et al. Effect of mosapride on Kv4.3 potassium channels expressed in CHO cells. Naunyn-Schmiedeberg's archives of pharmacology. 2013;386(10):905-16. [2]. Mine Y, et al. Comparison of effect of mosapride citrate and existing 5-HT4 receptor agonists on gastrointestinal motility in vivo and in vitro. The Journal of pharmacology and experimental therapeutics. 1997;283(3):1000-8. Chemical & Physical Properties Melting Point 112-114°C Molecular Formula C26H33ClFN3O6 Molecular Weight 538.00800 Exact Mass 537.20400 PSA 134.68000 LogP 4.62490 Storage condition 2-8°C |
| Use of | Mosapride (TAK-370) citrate dehydrate is a gastroprokinetic agent with 5-hydroxytryptamine4 receptor agonist activity and has been widely used in the research of a variety of gastrointestinal disorders. Mosapride citrate dihydrate potently inhibits Kv4.3 in a concentration-dependent manner with IC50 values of 15.2 μM[1]. Mosapride citrate dihydrateselectively stimulates upper GI motility in vivo[2]. Properties Name Mosapride Citrate Dihydrate Synonym More Synonyms Mosapride citrate Biological Activity Description Mosapride (TAK-370) citrate dehydrate is a gastroprokinetic agent with 5-hydroxytryptamine4 receptor agonist activity and has been widely used in the research of a variety of gastrointestinal disorders. Mosapride citrate dihydrate potently inhibits Kv4.3 in a concentration-dependent manner with IC50 values of 15.2 μM[1]. Mosapride citrate dihydrateselectively stimulates upper GI motility in vivo[2]. Related Catalog Research Areas >> Metabolic Disease Signaling Pathways >> Membrane Transporter/Ion Channel >> Potassium Channel Signaling Pathways >> GPCR/G Protein >> 5-HT Receptor Signaling Pathways >> Neuronal Signaling >> 5-HT Receptor 5-HT4 Receptor Kv4.3:15.2 μM (IC50) References [1]. Sung KW, et al. Effect of mosapride on Kv4.3 potassium channels expressed in CHO cells. Naunyn-Schmiedeberg's archives of pharmacology. 2013;386(10):905-16. [2]. Mine Y, et al. Comparison of effect of mosapride citrate and existing 5-HT4 receptor agonists on gastrointestinal motility in vivo and in vitro. The Journal of pharmacology and experimental therapeutics. 1997;283(3):1000-8. Chemical & Physical Properties Exact Mass 537.20400 PSA 134.68000 LogP 4.62490 |
| Transport Info | Shipping Name: UN |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 United Nations shipping name European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Danger Regulations: No International Maritime Danger Regulations International Air Transport Danger Regulations: No Marine pollutants (yes/no): No 14.6 Special reminder to users No data available |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| o-AdaMantylanisole | 43109-77-9 | 2A-0200745 |
| 2,2'-Bis-(1-adaMantyl)-4,4'-diMethoxybiphenyl | 932033-57-3 | 2A-0200746 |
| CHEMBRDG-BB 4024844 | 13125-62-7 | 2A-0200747 |
| 5-Deamino-5-oxo Amiloride Hydrochloride | 1207-29-0 | 2A-0200748 |
| [2R-[2α[R*(R*)],4β]]-α-[(AMinophenylacetyl)aMino]-4-carboxy-5,5-diMethyl-2 | 32746-94-4 | 2A-0200749 |
| Benzeneacetamide, N-(2-oxoethyl)- | 5663-61-6 | 2A-0200754 |
| PFE-360 | 1527475-61-1 | 2A-0200756 |
| N,N,beta-trimethyl-10H-phenothiazine-10-propylamine 5,5-dioxide monohydrochloride | 4784-40-1 | 2A-0200757 |
| PF-5190457 | 1334782-79-4 | 2A-0200758 |
| 4-((4,7,7-Trimethyl-3-oxo-bicyclo(2.2.2)hept-2-ylidene)methyl)benzenes ulfonic acid | 56039-58-8 | 2A-0200761 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS